Improving immunotherapy in solid tumors using FMT
Summary
Recent clinical trials demonstrate that fecal microbiota transplantation (FMT) enhances first-line immune checkpoint inhibitor efficacy in renal cell carcinoma, cutaneous melanoma, and non-small cell lung cancer with acceptable safety. Benefit appears mediated by functional microbiome remodeling, depletion of deleterious taxa, and systemic immunometabolic modulation, supporting microbiome-directed therapeutic strategies for cancer immunotherapy.
Content
# Improving immunotherapy in solid tumors using FMT
*Published: 2026 Apr 16*
Recent clinical trials demonstrate that fecal microbiota transplantation (FMT)
enhances first-line immune checkpoint inhibitor efficacy in renal cell
carcinoma, cutaneous melanoma, and non-small cell lung cancer with acceptable
safety. Benefit appears mediated by functional microbiome remodeling, depletion
of deleterious taxa, and systemic immunometabolic modulation, supporting
microbiome-directed therapeutic strategies for cancer immunotherapy.
DOI: 10.1016/j.cell.2026.03.021